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Introduction
In a series of experiments involving immunization with major histocompatibility complex (MHC)-incompatible mouse splenocytes osmotically loaded with chicken ovalbumin (OVA), Michael Bevan discovered that the antigen-presenting cells for MHC class I restricted OVA epitopes were necessarily recipient antigen-presenting cells [1] . This phenomenon was termed cross-priming, since the read-out was the ensuing activation of antigen-specific T cells. The set of mechanisms involving uptake, processing and presentation of cell-associated or soluble extracellular antigens receives the name of cross-presentation. Interestingly, MHC class I cross-presentation can lead to antigen-specific tolerance that can be referred to as "cross-tolerance" [2] . Dendritic cells (DCs) were identified as the subset of myeloid cells most efficient at cross-presentation [3] . Discoveries over recent years suggest that a very specific subset of DCs excels at cross-presentation [4, 5] , and equivalent subsets have been characterized in humans [6] [7] [8] [9] . While the demonstration of the relative cross-priming ability in different human DCs subsets requires further study [10, 11] , understanding and exploiting crosspriming is becoming very important in cancer immunotherapy, as it affects a variety of key issues ranging from the development of more efficacious vaccines [12] to understanding the effect of immunostimulatory monoclonal antibodies [13] . Figures 1 and 2 summarize antigen capture and cross-presentation by DCs in the tumor microenvironment (TME) and tumor-draining lymph nodes (LNs), and how targeting such DCs offers translational opportunities for the development of cancer therapies.
DC subsets specialized in cross-priming
Steinman and Cohn [14] first described DCs as a phagocytic cell type in mouse spleen with dendrite-shaped protrusions, which could prime and activate naive T cells upon antigen presentation [3] . Michael Lotze in mice [15, 16] and Ron Levy in humans [17] pioneered work to use DCs in tumor immunotherapy by incubation of DCs with tumor antigens in different forms to elicit tumor-specific T-cell immunity upon reinfusion of the antigen-loaded DCs into the tumor-bearing hosts. In most of these instances, the DCs used for immunotherapy were differentiated from monocytes in culture. Following exciting results against transplantable mouse tumors [18] [19] [20] , a large series of therapeutic vaccine clinical trials have been carried out but with as yet limited clinical efficacy [21] .
Over the years since their discovery, it has been revealed that DC lineage is very complex and encompasses a variety of subsets both in mice and in humans. DC heterogeneity adds an extra layer of complexity to instructing and manipulating immunity. Several DC subsets are functionally defined by their capacity to activate naive T cells, including conventional DCs (cDCs), plasmacytoid DCs (pDCs), Langerhans cells and monocyte-derived DCs [22] [23] [24] [25] . These DCs are subdivided based on their dependence on specific transcription factors in their ontogeny and show diverse functional responses, phenotypic markers and tissue Figure 2 . Summary of current therapeutic strategies that improve cross-priming of antitumor T cells. The intervention strategies for cancer treatment relying on tumor-antigen cross-priming are schematically represented in relation with the anatomical site of action. Of note, the doses of chemo or radiotherapy eliciting immunogenic cell death (ICD) are likely to be greater than those causing immunomodulation in the tumor microenvironment. DAMP, damage-associated molecular pattern; DC, dendritic cell; MDSC, myeloid-derived suppressor cell; TLR, toll-like receptor.
distribution [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . In addition, DCs can be differentiated in culture from monocytes or bone marrow precursors under the influence of granulocyte-macrophage colony-stimulating factor (GM-CSF), Flt3L or other cytokines [32] [33] [34] . These GM-CSFderived DCs generated ex vivo have been extensively used in experimentation with the caveat that they imperfectly reflect their naturally existing counterparts. pDCs comprise a subgroup of DCs dependent on the E2-2 transcription factor and co-express CD11c and PDCA1 (CD317) in mice, and BDCA2 (CD303) and BDCA4 (CD304) in humans. The main role of pDCs seems to be the abundant production of type I interferon (IFN-a/b) associated with viral sensing. IFN-a/ b is a factor known to enhance cross-priming [35] and reportedly, pDCs themselves can cross-present melanoma shared antigens in vitro [36] . The involvement of pDCs in cross-priming in vivo could be mostly indirect via type I IFN production although pDC direct involvement cannot be excluded.
Langerhans cells that are found in the epidermis are endowed with some antigen cross-presentation capability in humans [37, 38] and can migrate to draining LNs [37] . Probably, their main physiological role is antiviral defense of the skin [39] .
cDCs are best known for their high efficiency in initiating and directing T-cell responses [22, 24, 26, 27, 29] . In mice, cDCs express CD11c and MHC class II and can be subdivided into CD11b þ (cDC2) and CD11b -(cDC1) subsets [25] . cDC2 can be identified by surface coexpression of CD11b and SIRPa (CD172a) in mice, and BDCA1 (CD1c) in humans. cDC2 are dependent on the transcription factor IRF4 for ontogeny and include subsets defined by ontogenic dependence on Notch 2 or KLF4, associated with Th17 and Th2 immunity, respectively [40] [41] [42] . Indeed, cDC2s direct Th2 immunity in allergic asthma [43] .
CD11b -"CD8a-like" cDC1s comprise CD8a þ DCs in lymphoid organs and their CD103 þ CD11b -counterparts in nonlymphoid tissues that share gene expression patterns and depend on specific transcription factors, including IRF8 and BATF3 [44] . They have been recently reported to derive from a unique myeloid precursor [45, 46] . cDC1 express XCR1, CLEC9A/DNGR-1, CD8a and/or CD103 in mice, while in humans they can be best identified by XCR1, CLEC9A/DNGR-1 and BDCA3 (CD141) staining [47] . This subset very efficiently cross-presents extracellular antigens, particularly cell-associated antigens, to CD8 þ T cells [4, 44, [48] [49] [50] . When activated, cDC1s also produce high amounts of Th1-differentiating cytokines including IL-12, as observed both in human and in mice [8, [51] [52] [53] and provide essential signals for generation of resident memory CD8 þ T cells [54] . Although probably sculpted by evolution to initiate and sustain anti-viral immune responses [55] , the superior capacity of cDC1s for the induction of cytotoxic T lymphocyte (CTL) and Th1 responses makes them uniquely suitable for combatting cancer [4, 13, 56] . Recent evidence in transplanted mouse tumors shows the key role of cDC1s in the baseline CD8-mediated immune response against tumor antigens [4, 57] , while their presence in the TME of human tumors correlates with the intensity of CD8 T-cell infiltrates [58] [59] [60] . cDC1s come in two forms similarly fit for cross-priming. In the mouse, CD8a þ DCs are naturally resident in lymphoid tissues, whereas CD103
þ DCs lacking CD8a expression are deployed in peripheral tissues and upon activation migrate to LNs to meet T cells for antigen presentation. Given that these subsets are mainly involved in antiviral immune responses, it is likely that LN-resident cDC1s mainly deal with infections causing widespread viremia, while non-lymphoid tissue migratory cDC1s would handle viral infection at the point of entry.
More recently, cancer vaccination attempts have been made using reinfusion of defined populations of DCs obtained ex vivo upon immunomagnetic sorting from peripheral blood, including the use of BDCA1 þ and pDCs [61] [62] [63] . 
Intracellular molecular players in crosspresentation
MHC-I cross-presentation requires the processing and trimming of the endocytosed protein material. This processing takes place through two main intracellular routes: the cytosolic and the vacuolar pathways [49] . The cytosolic pathway requires antigen export of polypeptides from endosomal compartments into the cytosol [64] , proteasomal digestion [65, 66] and transporter associated with antigen processing (TAP)-dependent transport of polypeptides to the endoplasmic reticulum (ER) or endosomes, where final peptide trimming and MHC-I peptide loading take place. Inhibition of TAP in endosomes or inhibition of endosomal trafficking to the cell membrane leads to abrogation of soluble OVA protein cross-presentation in a cathepsin-independent fashion [67] . Trimming is carried out by ER-located aminopeptidase 1 [68] and the early endosome-associated protein insulinregulated aminopeptidase (IRAP) [69] . Both peptidases are required for optimal cell-associated antigen cross-presentation. An interesting experimental approach to deplete cross-presenting DCs is to inject cytochrome C in vivo, such that only those DCs with ability to cross-present that leak this pinocytosed protein to the cytosol undergo apoptosis [70] . The vacuolar MHC-I pathway is proteasome-and TAPindependent and does not require antigen to exit the endosomal compartment. In this case, endosomal protein cargo is degraded by lysosomal enzymes (cathepsins) and peptides are locally generated and trimmed to directly bind onto MHC-I molecules [71] . The exact relative contribution of the cytosolic and vacuolar pathways to tumor antigen cross-presentation in vivo remains unknown.
A distinctive feature of DCs specialized in cross-priming is their ability to maintain a higher pH in endosomal compartments, as compared with non-specialized DCs or macrophages. A higher endosomal pH delays antigen protein degradation, since lysosomal enzymes optimally perform in acidic conditions. Delayed acidification of prelysosomal or lysosomal compartments allows for protein export to the cytosol or its loading onto recycled MHC-I molecules in the endosome. This slow acidification mechanism is mediated by the phagosomal NADPH oxidase NOX2, which catalyzes reactive oxygen species production and proton consumption in phagosomes [72, 73] . In this context, the G-protein Rac2 is required for the effective action of NOX2 in lysosomes [74] . Sec22b is reportedly another key molecular player, bringing together ER-derived vesicles (ER-Golgi Intermediate Compartments, ERGIC) and phagosomes for fusion, while delaying antigen proteolytic degradation in endosomes [75] . It must be acknowledged that the molecular machinery defining uptake and MHC-I crosspresentation of tumor cell-associated antigens still defies complete understanding.
Evidence for cross-presentation and crosspriming in cancer immunology
Tumor antigen cross-presentation is postulated to be naturally and constantly taking place. Batf3-deficient mice, in which crosspresentation is severely reduced, are more susceptible to tumor engraftment than their wild-type counterparts [4] . Crosspresentation of tumor antigens is frequently demonstrated with the help of known surrogate antigens expressed by tumor cells, the most common being chicken OVA, although other viral or neoantigens known to be present in tumor cell lines could be used in this same way. These surrogate antigens stimulate T-cell receptor transgenic lymphocytes, e.g. OT-I CD8 þ T cells recognizing an H2-K b -restricted peptide of OVA. Most tumor antigens are probably cross-presented as cell-associated material by Batf3-dependent cDC1s [44] , rather than soluble individual proteins. cDC1s show high efficiency at endocytosis of material from dying or dead cells, and from subcellular vesicles such as exosomes [76] [77] [78] [79] [80] . However, the superior capacity of cDC1s for cross-presentation is attributable to their specialized antigenprocessing capacity [81, 82] . The cross-presentation ability of cDC1s is also favored by the selective expression of receptors such DNGR-1 (CLEC9A) on their surface [83] [84] [85] . DNGR-1 facilitates cross-presentation of necrotic material upon interaction with filamentous actin onto which other proteins can be adsorbed and complexed [86, 87] . In situ tumor antigen capture is similar among different tumor-infiltrating DCs (TIDCs), monocytes and tumor-associated macrophages (TAMs) [58, 88] , but cDC1s uniquely mediate the transport of antigens for cross-presentation from the tumor to the draining LN for cross-priming of CD8 þ T cells [60, 88] .
Some controversy exists surrounding the superiority of BDCA3 þ cDC1s in cross-presentation of cell-associated antigens in humans [6] [7] [8] [9] 11] . Whether or not BDCA3 þ cDC1s outperform other DC subsets in cross-presentation activity in cancer patients still remains unclear. However, mounting evidence suggests that the presence of BDCA3 þ cDC1s in the TME is associated with more abundant T-cell infiltration and better prognosis in cancer patients and the success of immunotherapy approaches [57] [58] [59] . Of note, there is no published formal experimental evidence that neoantigens can be cross-presented yet.
Does T-cell cross-priming take place in the TME and/or in tumor-draining LNs?
As stated above, although macrophages and other DC subsets phagocytose tumor antigens, CD103 þ cDC1s mediate tumor antigen transport and cross-presentation from established tumors and early metastases to LNs [13, 58, 60, 79, 88, 89] . The role of LN-resident DCs in tumor antigen cross-presentation is unclear. A potential tumor antigen transfer mechanism from CD103 þ to other LN DC populations has been proposed [60] .
þ DCs revealed superior expression of genes involved in cross-presentation, costimulation ability and IL-12 production over non-BATF3-dependent DCs, suggesting that their role could be carried out in the TME [58] . Depletion of cDCs hampered an adoptive T-cell therapy experiment in which LN priming would be dispensable, suggesting that the intratumoral presence of ZBTB46 þ cDCs is a requirement for the continuous priming of the transferred T cells [58] . In line with this, in situ activation of naive T cells in tumors was possible in experiments in which T-cell recirculation was blocked with FTY-720 and even in mice lacking LNs and spleen, thus pointing to T-cell activation by TIDCs and/or tumor cells themselves [90, 91] . However, other studies have reported no tumorassociated antigen (TAA) cross-presentation from CD11c-sorted cells from the TME [92] . A potential limitation of this and other reports is the use of CD11c expression as the exclusive marker to identify TIDCs, which may include a majority of TAMs in the subsequent functional analyses [93] . Recent reports refining the isolation of cDC1 from the tumor site confirmed that these cells are able to cross-present tumor antigen with a higher efficiency than other DC subsets [58, 89] . In addition to DCs, it is possible that other cells such as lymphatic endothelial cells cross-present TAA in the TME and in TDLNs, but their function seems to be more closely related to cross-tolerance than to eliciting antitumor immunity [94] .
Immunosuppressive factors for DCs in the TME
Tumor-derived factors influencing DC function have been recently reviewed in detail by the group of Michael Shurin [95] . TIDCs are exposed to tumor-associated and extracellular immunoregulatory factors that may render DCs non-functional or even actively immunosuppressive [96] . These deleterious mechanisms comprise metabolic, immune-mediated, biochemical or mechanical factors (Figure 1) .
A very important signaling route that is involved in crosspriming inhibition in tumors is controlled by the b-catenin pathway. Previous work suggested that the activation of b-catenin signaling favors a tolerogenic state in DCs [97, 98] . Wnt ligands and other molecules promoting b-catenin signaling, both in tumor cells and inside DCs, mediate DC exclusion from the TME and the inhibition of their antitumor immune functions, respectively. The group of Thomas Gajewski identified melanoma cell-intrinsic bcatenin signaling as the main cause for a downregulation of CCL4 production and hence of DC chemoattraction. As a result, there is T-cell exclusion from the TME [57] (While this review was in editorial production, the findings in [57] were confirmed and cDC1 cells were found, in an experimental melanoma model, to be key to chemoattract CD8+ T cells to the TME by means of CXCL9 and CXCL10 production [99] . Also, CXCL9 and CXCL10 mRNA in human melanomas were found to correlate with a gene signature denoting cDC1 infiltrate.). DC-intrinsic b-catenin signaling is also active in TIDCs, and it both disrupts cross-presentation and reprograms DC to induce tolerance, generating T regulatory cells (Tregs) as a result of their TGFb production [100] . In some cases, Wnt ligands are tumor derived [101] . Ensuing IDO-1 expression has been proposed as one of the mechanisms underlying tolerization by DCs [102] . This enzyme causes tryptophan depletion and production of immunosuppressive kynurenine and other metabolites in the TME [103] [104] [105] .
It should not be forgotten that the physical and chemical conditions of the TME affect the functions of the leukocytes that dare to infiltrate the malignant tissue. Solid tumors contain large hypoxic areas, due to poor vascularization and the leaky nature of tumorirrigating blood vessels. Hypoxia has been shown to cause a shift toward glycolytic metabolism and increased responsiveness to LPS stimulation in DCs [106] . It has also been observed that hypoxia exposure reduces IL-12 production by DCs [107] , which is partially rescued by HIF-1a silencing [108] . The specific contribution of the hypoxic tumor environment to the maturation status and function of TIDCs has still to be determined. The overall picture is that while hypoxia dampens the antitumor functions of myeloid cells, it improves the performance of T cells [109] .
A glycolytic switch is characteristic of both DC and T-cell activation to an effector phenotype [110] . Glucose availability in the TME is a critical limiting factor for T-cell activation and function [104, 111] . The local concentration of certain aminoacids and waste metabolites also dramatically influences T-cell and DC function in the tumor, often dampening antitumor immune responses [112, 113] . TIDCs are prone to accumulation and oxidization of lipid bodies [114] , which can hamper efficiency of cross-priming and produce other dysfunctions through chronic induction of the ER stress response [115] [116] [117] . Hence, targeting metabolic pathways in TIDCs might represent an interesting opportunity for cancer immunotherapy [118, 119] .
There is ample evidence that functional immune cell receptors acting as checkpoints [120] repress anti-cancer immunity [121] . DCs express high levels of PD-L1 and PD-L2 upon stimulation [88] . PD-1 expression has also been demonstrated on TIDCs in human cancerous tissue and blood [122] , as is also the case with the coinhibitory receptor Tim-3 [123] . The expression of these checkpoints and their counter-receptors on DCs interferes with the DC maturation processes inhibiting NF-jB activation [122] , HMGB1 function as TLR4 agonist [123, 124] and cytosolic nucleic acid recognition in the TME. Therefore, checkpoint surface molecules on DCs ultimately exert a negative effect on the cross-priming of T cells. Whether or not the expression of these checkpoint molecules on DCs is directly involved in the clinical antitumor efficacy of PD-1/PD-L1 blockade is an issue that remains to be elucidated.
TIDC differentiation from circulating monocytes is also affected by tumor-derived factors such as M-CSF (CSF1) and IL-6, which favor macrophage differentiation [125] . TAMs are great producers of IL-10 in the TME [126] , which is known to act as an immunosuppressive factor for cross-priming DCs [51] .
Activation of TIDCs by administration of TLR agonists such as poly:IC (TLR3) or imiquimod (TLR7/8), among other strategies, aims to reverse their tolerogenic status [13, [127] [128] [129] (Figure 2) . A strategy currently being tested in clinical trials against melanoma involves local transfection of TIDCs using mRNA encoding for T-cell costimulatory molecules [130] [131] [132] . Transfection of IL-12 into ex vivo-generated DCs for intratumoral injection has also been reported to improve antitumor responses in mice and humans [133, 134] .
Immunogenic cell death and cross-priming
The concept of immunogenic cell death (ICD) proposed by Guido Kroemer and collaborators [135] [136] [137] is intimately bound to the concept of tumor immunogenicity, cross-priming and DC function. ICD can induce an adaptive effector immune response against antigens present in the dying cell [138] . It is important to remember that ICD is an active process within the dying cell, which releases alarmins and chemotactic factors leading to DC attraction and activation (Figure 3) .
DCs are key mediators in the building of an immune response against cells undergoing ICD. ICD activates antigen crosspresentation in several ways: (i) attracting cross-presenting DCs to dying cells (i.e. ATP, mitochondrial formyl peptides) [91, 139] , (ii) increasing the uptake and processing/presentation of dead cell-associated antigens by DCs (i.e. exposure of calreticulin, heat shock protein 70, exposure of phosphatidylserine) [140, 141, 142] and (iii) licensing DCs for CTL activation (i.e. HMGB1 acting on TLR4 or ATP acting in P2X 7 ) [141, 143, 144] . An interesting mechanism has been reported in this regard: CD24 on cDC1s can adsorb HGMB1 to be trans-presented to RAGE on T cells [124] . Accordingly, in the absence of DCs, responses against vaccines or conventional anti-cancer treatments inducing ICD are impaired [91, 143, 145] .
Hypericin-based photodynamic therapy [145] , radiotherapy [146, 147] , certain chemotherapeutics [91, 138] and other interventions [148] have been demonstrated to elicit ICD in vitro and are candidate strategies for cancer vaccine preparation. Cell freezing and thawing is widely regarded as generator of a nonimmunogenic necrotic death and, as a result, does not lead to efficient antigen cross-priming [145] . However, a simple heating step following cell lysis might halt protein degradation by peptidase inactivation and allow for T-cell cross-priming [149] .
A recent paper by the group of Matthew Albert identified a cancer cell-intrinsic RIPK1-NF-jB signaling pathway that was required for a form of programmed necrosis called necroptosis [150] . Mice immunized with necroptotic cells established stronger responses than those immunized with apoptotic or frozen/ thawed cells. Immunization again was dependent on crosspriming by Batf3-dependent DCs. Similar results were obtained in an additional publication using CT26 necroptotic cells [151] . No mechanism has been reported so far linking necroptosis to facilitated cross-priming.
This concept of ICD is reminiscent of the postulates of the danger model originally proposed by Polly Matzinger, according to which the immune system is set up to respond to agents causing tissue and cell damage [152] . The overall concept is that alarmins released or exposed [153] during ICD change the functional profile of DCs, even in sterile conditions, in a process known as maturation or activation. As a consequence, costimulatory molecules for T cells become expressed on the plasma membrane along with abundant MHC-antigen complexes and IL-15Ra coupled to IL-15 on the DC surface that is thereby trans-presented to signaling receptors on T cells [154] . The induction of IL-12 and ligands for T-cell costimulatory receptors of the tumor necrosis factor receptor (TNFR) family such as CD27L (CD70), CD137L, OX40L [155] [156] [157] are considered paramount in this process (Figure 3 ).
Targeting tumor antigen to DCs to favor its cross-presentation
An attractive way that has been explored for immunization against tumors is the targeting of tumor antigens to DCs using monoclonal antibodies (mAbs) directed to DC surface receptors that internalize upon ligation.
The group of Ralph Steinman efficiently targeted antigen to the DC surface receptor DEC205 [158] . Using this strategy, CD8-and CD4-mediated responses were generated, the former being TAP-dependent. Without coadministration of an agonist anti-CD40 monoclonal antibody (mAb) as a DC-activating adjuvant, vaccination was actually tolerogenic. This effect was mainly mediated by CD8a þ cDC1s in the mouse. DEC205 targeting directs the antigens to late endosomes and lysosomes [159] . Targeting antigens to CD40, unlike DEC205, delivers antigen to early EEA1 þ endosomes and is a more efficient strategy for crosspresentation. This is consistent with the notion that intracellular trafficking to early endosomes is required for efficient crosspresentation. Targeting to CD40 potentiates cross-priming by both Batf3-dependent and Batf3-independent DCs, reportedly achieving better responses than those obtained by anti-DEC205 antigen complexes [159] . This strategy is being pursued in clinical trials with anti-DEC205 mAb linked to NYESO-1 antigen (NCT01834248, NCT02166905).
DNGR-1 (CLEC9A) is an internalizing receptor with high expression narrowly restricted to cDC1s in mouse and humans, although it shows low expression on other cell types [84, 85, 160, 161] . Its main function may be the routing of necrotic cellderived material into nonlysosomal compartments for crosspresentation [55, 162, 163] . Targeting cDC1s with protein antigens coupled to anti-DNGR-1 mAbs was much superior to control IgG-bound antigen in generating antitumor immune responses, when combined with adjuvants such as anti-CD40 or poly:IC [84] . In a similar manner, coupling TAA to a short peptide that targets DNGR-1 has been shown to induce antitumor immunity [164] .
Since cDC1s selectively express the chemokine receptor XCR1, targeting of this receptor with a construct of its ligand XCL1 coupled with antigen was also effective in inducing CD4 and CD8 T-cell-mediated responses against viral infection [165] .
A caveat for the formulation of antigens targeted to DC receptors is that the nature of the most immunogenic tumor antigens is usually ignored. Indeed, the most powerful tumor antigens are the result of unique non-synonymous mutations in their translated genes whose peptide sequences fit the autologous MHC-I and MHC-II alleles acting as antigen-presenting molecules. Such antigens specific to each tumor are named neoantigens. The use of cancer neoantigens for vaccination holds much promise for the delivery of efficacious immunotherapy strategies [166] , particularly when combined with checkpoint inhibitors [167] . Targeting neoantigens to cross-priming DCs seems to be a reasonable strategy, but preparing individual DC-targeting moieties for each patient is a daunting biotechnical challenge. mRNA coding for neoantigens and/or shared antigens has been complexed with liposomal carriers and administered systemically, generating potent vaccine-specific antitumor immunity in a DC-dependent way, provided that the charge and size of the lipoplexes is optimized [168] . This approach, using neoantigens and shared tumor antigens, is currently being tested in clinical trials against melanoma and breast cancer (NCT02410733, NCT02316457). Alternatively, naked synthetic mRNA encoding cancer neoantigens can be injected inside LNs with ultrasound guidance achieving powerful vaccine effects [169] .
Cross-priming involvement in various cancer therapies
We will briefly discuss the involvement of cross-priming in currently used therapeutic strategies and the potential for improvement of both cytotoxic therapy and immunotherapy upon combination with cross-priming enhancers.
Chemotherapy
Chemotherapy can improve immunotherapeutic approaches in two main ways: first, by inducing ICD of tumor cells, allowing for antitumor T-cell cross-priming by native DCs; second, by modulating the phenotype of tumor-associated regulatory populations such as regulatory T cells (Tregs), TAMs or myeloid-derived suppressor cells. It is now well known that not all chemotherapeutic agents induce ICD [136] : anthracyclines such as doxorubicin or mitoxantrone [138, 140] and cyclophosphamide [170] are strong inducers of ICD and tumor antigen cross-presentation, while cisplatin is not [171] . Additionally, systemic gemcitabine was shown to recover dysfunctional cross-presentation by TAMs and TIDCs [92] whereas it was ineffective in cDC1-deficient Batf3 -/-mice [172] . One report pointed to a Batf3-independent subset of tumor-infiltrating CD11c þ CD11b þ Ly6C hi cells as responsible for the ensuing immune response to ICD induced by anthracyclines [91] . This suggests a more complex interplay of immune cells involved in the response to chemotherapy. The proimmune effects of chemotherapy may need lower doses than the maximally tolerable dose levels used as a standard [173] . All in all, the line of work pioneered by Guido Kroemer and Laurence Zitvogel puzzled the world of clinical oncology, since in mouse models some forms of chemotherapy act against tumors with an absolute need for cellular immune responses dependent on ICD [135] .
Radiotherapy
Ionizing radiation is an ICD inducer, and therefore a good candidate for successful combination with immunotherapy [138, 174, 175] . Radiotherapy (RT) has been shown to potentiate tumor antigen cross-presentation in mouse models [176] . Several groups explored the intratumoral injection of DCs into irradiated mouse tumor models with positive results [177, 178] . The functions of cDC1s sensitive to IFNa have been found to be very important for the immune-mediated therapeutic effects of local irradiation [179] . These findings are consistent with the requirement for DCmediated cross-priming in mouse models in which RT induces abscopal effects to concomitant non-irradiated tumors, that can be greatly potentiated with immunomodulatory anti-PD-1, anti-CTLA-4 and anti-CD137 mAbs [180] [181] [182] [183] [184] . It should be kept in mind that TIDCs under the irradiation beam also undergo functional changes [185] . Curiously, a conversion from pro-to antitumor myeloid populations occurs in the TME of tumors irradiated at low doses [186] . Active combinations of RT and local TLR agonists have been preclinically reported [187] and clinically tested against follicular lymphoma [188] and breast cancer [189] .
Immunotherapy
Type I IFN (IFNa/b) potentiates cross-presentation by DCs [35] and it has been found to be clinically active against a number of malignancies [190] . The antitumor activity of type I IFN requires type-I IFN receptor (IFNAR) function on cDC1s in mouse models [191, 192] . IFNAR absence in CD11c cells leads to reduced intratumoral accumulation of DCs and decreased crosspresentation capability on a per-cell basis. The antitumor effect of anti-CD47 is also dependent on IFNAR and this agent is known to potentiate antigen cross-presentation by DCs and macrophages both at the tumor site and in TDLNs [193] . CD47 functions as a ligand for SIRPa, acting as a don't-eat-me signal. Accordingly, if anti-CD47 mAb disrupts this inhibitory interaction, more phagocytosis takes place. Conceivably IFNa/b enhances cross-presentation and cross-priming against the cellassociated endocytosed material.
Stimulator of IFN genes (STING) agonists are potent type I IFN inducers [194] . Not surprisingly, local immunotherapy based on STING agonist cyclic dinucleotides given intratumorally absolutely requires STING expression in Batf3-dependent DCs [195] and this function is required to enhance the therapeutic results of immune checkpoint blockade in the B16 melanoma mouse model [196] .
Immune checkpoint blockade with anti-PD-1/PD-L1 and anti-CTLA4 has been demonstrated to be ineffective in Batf3-deficient mice [13, 88, 167] . Moreover, Batf3-dependent DCs are critical for the antitumor activity of anti-CD137 agonist immunostimulatory mAbs [13] . In fact, systemic DC expansion and local stimulation with Flt3L and poly-ICLC synergized with PD-1/ PD-L1 blockade and CD137 stimulation [13] or mutant BRAF inhibition [88] . These results suggest that the numbers of such DCs mediating cross-priming and their activation status can be modulated to enhance other immunotherapy interventions.
Conclusion
Direct presentation by malignant cells of tumor antigen to T cells is crucial at the effector killing phase, but inefficient to prime and sustain the cytotoxic immune response [197] . Cytotoxic T lymphocytes need therefore to recognize their cognate antigen on professional antigen-presenting cells. Only a few years ago, crosspriming was a black box in terms of our mechanistic knowledge [198] . The molecular and cellular details on how, where and under which circumstances cross-presentation of tumor antigens efficiently takes place are crucial for understanding immune responses against tumors and will certainly provide multiple opportunities for progress in cancer immunotherapy.
